



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	☒ CD4+ N#2 500 T-cell line
Catalog Number:	12533
Lot Number:	140317
Release Category:	C
Provided:	1 mL of 3.7^6 cells. Viability is 82%.
Cell Type:	Herpesvirus saimiri (HVS)-transformed CD4+ T-cell-line
Propagation Medium:	RPMI with 10% FBS and IL2 at 100 U/mL.
Growth Characteristics:	<p>The cells grow in suspension with small clumps and have a doubling time of 24 hours. Cells act very similar to primary T cell cultures. They may be sensitive to the FBS lot that is used. If growth is poor, attempt switching FBS lots. They should be cultured at concentration 0.5×10^6 cell/ml. Of note the donor suggests that thawing should be done quickly at 37°C for only 2 minutes then transferred to T75 Flask with 10 ml of warm medium.</p> <p>If you have trouble culturing the cells, please contact Dr. Arevik Mosoian, arevik.mosoian@mssm.edu.</p>
Morphology:	T cell-like
Description:	The CD4+ T-cell line N#2 500 is a Herpesvirus saimiri (HVS) transformed CD4+ T cell line isolated from an infected Caucasian donor. The cell culture supernatant has been shown to suppress infection with HIV-BaL in primary human macrophages and infection with HIV-BaL and IIIB in primary human CD4+ T cells.
Recommended Storage:	Liquid Nitrogen

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Contributor: Arevik Mosoian

References:

1. Mosoian A, et al. (2006) Novel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophages. *J Virol* 80(18):9200-9206.
2. Mosoian A, et al. (2010) Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction. *Proc Natl Acad Sci U S A* 107(22):10178-10183.

NOTE: Acknowledgment for publications should read "CD8+ T-cell line K#1 50K cat#12533 was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from Dr. Arevik Mosoian." Also include the reference cited above in any publications.

Last Updated July 05, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.